Literature DB >> 18275349

Dissociated production of perforin, granzyme B, and IFN-gamma by HIV-specific CD8(+) cells in HIV infection.

Stefanie Kuerten1, Tobias M Nowacki, Thomas O Kleen, Robert J Asaad, Paul V Lehmann, Magdalena Tary-Lehmann.   

Abstract

CD8(+) T cells play a crucial role in the control of viral infections such as HIV. The functional characterization of HIV-specific CD8(+) T cells has so far been largely restricted to studies of IFN-gamma. The TCR-triggered release of the effector molecules perforin (PFN) and granzyme B (GzB), however, is thought to be a central pathway for the destruction of virus-infected target cells by CD8(+) effector T cells. Here we would like to address two major findings. On the one hand we propose that ex vivo measurements of PFN and GzB secretion via ELISPOT may permit the distinction between in vivo resting versus activated CD8(+) memory T cells in healthy and HIV-infected individuals. Therefore, extending the present standard of IFN-gamma measurements to the analysis of PFN and GzB release in functional T cell assays will provide new insights into CD8(+) effector T cell functions. It should enable the evaluation of therapeutic vaccination efficacy by its ability to reactivate and convert IFN-gamma-positive, but GzB- and PFN-negative memory CD8(+) T cells into PFN/GzB-secreting effector cells. On the other hand, we report on a frequent ex vivo dissociation of the HIV peptide-induced secretion of PFN and GzB in chronic HIV infection underlining CD8(+) effector T cell diversity in this disease--an aspect that also has to be accounted for in immune monitoring approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275349     DOI: 10.1089/aid.2007.0125

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  Fas/FasL and perforin-granzyme pathways mediated T cell cytotoxic responses in infectious bursal disease virus infected chickens.

Authors:  Abdul Rauf; Mahesh Khatri; Maria V Murgia; Yehia M Saif
Journal:  Results Immunol       Date:  2012-05-16

2.  Correlation of HIV-specific immunity, viral control, and diversification following planned multiple exposures to autologous HIV in a pediatric population.

Authors:  William Borkowsky; Elizabeth J McFarland; Ram Yogev; Yonghua Li; Paul Harding
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

3.  NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses.

Authors:  Andrew Zloza; Frederick J Kohlhapp; Gretchen E Lyons; Jason M Schenkel; Tamson V Moore; Andrew T Lacek; Jeremy A O'Sullivan; Vineeth Varanasi; Jesse W Williams; Michael C Jagoda; Emily C Bellavance; Amanda L Marzo; Paul G Thomas; Biljana Zafirova; Bojan Polić; Lena Al-Harthi; Anne I Sperling; José A Guevara-Patiño
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

4.  Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.

Authors:  Julia Pohling; Katrin Zipperlen; Natasha A Hollett; Maureen E Gallant; Michael D Grant
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

5.  Lack of disease specificity limits the usefulness of in vitro costimulation in HIV- and HCV-infected patients.

Authors:  Stefanie Kuerten; Tobias R Schlingmann; Tarvo Rajasalu; Doychin N Angelov; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  Clin Dev Immunol       Date:  2008

6.  ELISPOTs Produced by CD8 and CD4 Cells Follow Log Normal Size Distribution Permitting Objective Counting.

Authors:  Alexey Y Karulin; Kinga Karacsony; Wenji Zhang; Oleg S Targoni; Ioana Moldovan; Marcus Dittrich; Srividya Sundararaman; Paul V Lehmann
Journal:  Cells       Date:  2015-01-20       Impact factor: 6.600

7.  High Reproducibility of ELISPOT Counts from Nine Different Laboratories.

Authors:  Srividya Sundararaman; Alexey Y Karulin; Tameem Ansari; Nadine BenHamouda; Judith Gottwein; Sreenivas Laxmanan; Steven M Levine; John T Loffredo; Stephanie McArdle; Christine Neudoerfl; Diana Roen; Karina Silina; Mackenzie Welch; Paul V Lehmann
Journal:  Cells       Date:  2015-01-09       Impact factor: 6.600

8.  Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease.

Authors:  Tobias M Nowacki; Dominik Bettenworth; Matthias Ross; Jan Heidemann; Paul V Lehmann; Andreas Lügering
Journal:  Cells       Date:  2012-04-23       Impact factor: 6.600

9.  Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T Cell ELISPOT Assays.

Authors:  Stefanie Kuerten; Helena Batoulis; Mascha S Recks; Edith Karacsony; Wenji Zhang; Ramu A Subbramanian; Paul V Lehmann
Journal:  Cells       Date:  2012-07-30       Impact factor: 6.600

10.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.